On Wednesday in Rabat, the agency launched VigiMobile and VigiUp, two digital channels for reporting suspected adverse events linked to health products. VigiMobile is a mobile app for medicines and vaccines. VigiUp covers everything else: medical devices, in vitro diagnostic reagents, cosmetics, personal hygiene products and dietary supplements.

Both are accessible through the AMMPS website. Patients, healthcare professionals, and companies that manufacture, import or distribute health products can all file reports. Online reporting is open around the clock. Paper forms still exist, but users must download the document, complete it and email it to the address printed on the form. That is a lot more effort than tapping a screen.

How does it work?

A report submitted through either platform goes to the National Center for Health Vigilance and Risk Management. The center monitors and analyzes product risks after they reach the market, looking for patterns that a single clinic or a single patient would never spot.

The split between the two tools is practical. Medicines and vaccines have their own reporting channel in the app. Devices, diagnostics, cosmetics and supplements, which have historically had less visibility in safety systems, go through VigiUp. So a patient who reacts badly to a skin cream and a nurse who sees a faulty device now have a clear place to go.

The launch took place during Med Safety Week 2026, an international campaign running from November 2 to 8 under the slogan “Adverse events, don’t ignore them, report them.” A panel at the ceremony covered how clinicians can identify and report events. The agency is also running university outreach for future health professionals and local activities with Regional Vigilance Centers.

Why does it matter?

Because the existing system has real holes. A 2025 study in Drug Safety assessed pharmacovigilance across 30 Moroccan university hospitals. Electronic reporting to the national center was used in just one. Seven hospitals, or 23%, had no established pharmacovigilance activity or only very basic work. Two of the four university hospital centers with established monitoring were underreporting to the central database.

Earlier research points to familiar reasons: time pressure, uncertainty about what counts as reportable, fear of consequences, and no feedback after a report is filed. An app solves the first problem. It does not automatically solve the others.

Health and Social Protection Minister Youns Bjijou, in remarks read by ministry Secretary-General Abdelkrim Meziane Belfkih, called for stronger reporting practices and closer coordination between national and regional health actors. AMMPS Director General Samir Ahid said monitoring must continue after marketing authorization, with early risk detection. Both are right. But the test is whether reporters hear back and whether hospitals actually use the tools.

The context

This is part of a wider digital push at the agency. On March 31, the AMMPS launched TARKHISS to digitize regulatory procedures for health products, starting with cosmetics and personal hygiene products. The World Health Organization has also credited digital reform with improving Morocco’s mortality data system.

The direction matches what is happening across the Gulf and the wider Arab region. Saudi Arabia under Vision 2030 and the UAE through its national digital health strategies have pushed electronic reporting and unified health records, partly to make safety data usable in real time. Regulators in the GCC face the same problem Morocco does: a good reporting system is worthless if clinicians do not use it.

For manufacturers and importers, the message is also clear. Companies can report through these channels, and regulators will expect them to. Post-market vigilance is becoming a daily obligation, not a paperwork exercise. Morocco has built the door. Now it has to get people to walk through it.

The post Morocco makes it easier to report a bad reaction to a medicine appeared first on DH Arab.

The two organisations have signed an agreement setting out a framework for cooperation in education, capacity building and innovation. It covers joint learning, knowledge sharing, and the use of gamification to give learners the skills to build healthcare solutions. Dr. Hanan Al Suwaidi, Deputy CEO and Chief Academic Officer of Dubai Health and Provost of Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), signed for Dubai Health. Mona Ghander, Senior Vice President of Innovative Solutions and Strategic Partnerships, signed for AGF.

How will it work?

The first product of the agreement is a 16-week Game Development Bootcamp for Graduate Medical Education trainees at MBRU. Dubai Health and AGF are running it with the United Nations Development Programme Istanbul International Center for Private Sector in Development (UNDP IICPSD) and HP Inc.

Participants will work with mentors from the gaming industry, academic advisors and Dubai Health clinicians. They will build gamified tools aimed at public health priorities set by Dubai Health itself. So the brief does not come from a textbook. It comes from the system the trainees will eventually work in.

Trainees will combine clinical knowledge with game development, design thinking and wider digital skills. The bootcamp is only the start. The agreement also lays the ground for joint research and development, innovation competitions, internships, short courses and workshops, involving faculty, students, staff and clinical teams.

Why does it matter?

Medical training rarely leaves room for product design. This programme makes room for it. Dr. Wail Bamadhaf, Vice Dean of Graduate Medical Education at MBRU, said the future of health will be shaped by professionals who combine clinical knowledge with digital fluency. Ghander made a similar point from the education side, saying digital skills matter most when learners apply them to real challenges.

Gamification is not a gimmick in health. Done well, it can support patient education, prevention campaigns and adherence to treatment. But it only works when clinicians shape the content. That is the gap this bootcamp tries to close, by putting people who understand patients next to people who understand engagement.

The context

The partnership fits a wider pattern across the Gulf. Governments in the GCC want health systems that are digital, preventive and built on local talent, and that goal runs through Saudi Vision 2030, UAE health strategies and national digital transformation plans. Training clinicians to build tools, not only use them, is one practical way to get there.

For AGF, the deal extends its established work on linking education to employment through practical, industry-relevant learning. Healthcare is a new setting for that model, and a demanding one.

Still, the real test comes later. A bootcamp can produce prototypes. What matters is whether any of them reach patients and whether the longer-term framework turns into funded research, internships and lasting programmes. If it does, Dubai Health will have a model other GCC institutions are likely to study closely.

The post Dubai Health teaches doctors to build games appeared first on DH Arab.

Spasticity is one of the most draining symptoms of MS. Muscles tighten and stiffen without warning, walking becomes difficult, and pain follows. For patients with focal spasticity in the lower limbs, daily life can shrink to whatever they can manage between episodes.

How did it work?

Cryoneurolysis uses extreme cold to temporarily disrupt a specific nerve. The clinicians identify the nerve driving the overactive muscle, then apply a very low temperature to it through a thin probe. The cold interrupts the pain and spasm signals travelling along that nerve, without destroying the nerve’s structure. That matters, because the nerve can regenerate over time.

The procedure is minimally invasive. The team at Cleveland Clinic Abu Dhabi used it on the patient’s lower limbs, and the severe focal spasticity went down. Because the treatment is aimed at one nerve rather than the whole body, it avoids many of the side effects that come with oral medication.

Why does it matter?

MS patients often cycle through muscle relaxants, injections and physiotherapy, and each has limits. Oral drugs can cause drowsiness and weakness. Injections wear off and must be repeated. A local, drug-free option adds something genuinely different to the toolbox.

The benefits for patients are practical:

• Less stiffness and pain in the affected limb
• Better movement and easier participation in rehabilitation
• Fewer systemic side effects than oral treatment
• A short, minimally invasive procedure

But one case is not a trial. Clinicians will need to follow how long the relief lasts and which patients benefit most. Those answers will decide whether cryoneurolysis becomes routine or stays a specialist option.

The context

This result fits a clear pattern in the Gulf. Abu Dhabi has spent years positioning itself as a centre for advanced care, and the UAE’s health strategy rewards hospitals that bring new techniques home rather than sending patients abroad. Saudi Arabia’s Vision 2030 health goals push the same way, with a focus on specialised services delivered locally.

Neurological disease is part of the reason. MS is not rare in the region, and patients often need years of coordinated care. Offering advanced symptom management close to home reduces travel, cost and disruption for families.

So the freeze itself is small. The signal is larger. When a hospital in Abu Dhabi can be the first in the country to offer a technique like this, it tells patients and policymakers that the region’s medical capability is catching up with its ambition. The next step is evidence, and that means more patients, longer follow-up and published results.

The post Abu Dhabi freezes a nerve to calm MS spasticity, a first for the UAE appeared first on DH Arab.

The two organisations have signed a Memorandum of Understanding to advance academic research in rehabilitation, long-term care and specialised care. The agreement pairs CHG’s clinical expertise in long-term and specialised care with the university’s research strength. That is the core of the deal: practitioners who see patients every day working with academics who can test, measure and publish.

An MoU is a framework, not a finished study. The announcement does not list specific projects, budgets or results, so it is too early to judge what the collaboration will produce. But the focus areas are clear, and they are ones where evidence is often thinner than clinicians would like.

How will it work?

The partnership runs for three years and centres on shared academic research. In practice, that usually means joint studies, access to clinical settings for researchers, and a route for findings to return to the bedside. CHG supplies the patients, the care pathways and the day-to-day clinical insight. Heriot-Watt supplies research methods, analytical capacity and academic rigour.

The three areas named in the agreement are:

• Rehabilitation, from recovery after illness or injury to restoring function
• Long-term care, including support for patients with chronic and complex needs
• Specialised care, where treatment pathways are narrower and data is harder to collect

Details of individual projects have yet to be announced.

Why does it matter?

Long-term and rehabilitative care is where healthcare systems feel demographic pressure first. Populations are ageing, chronic disease is common, and more people survive serious illness and need support afterwards. The GCC is no exception. Diabetes, cardiovascular disease and road trauma all create demand for sustained rehabilitation.

And yet these services often run on practice habits rather than local evidence. Research carried out in the UAE, on UAE patients, would help providers decide which interventions work, for whom, and at what cost. For policymakers, that kind of data is hard to replace. For private operators, it supports better care models and clearer conversations with insurers.

The context

The deal fits a wider regional push. Across the Gulf, national strategies, including Saudi Vision 2030 and the UAE’s health agenda, call for stronger private-sector participation, higher-quality care and a research base that does not depend entirely on imported findings. Linking operators with universities is one of the quicker ways to build that base.

It also reflects how Gulf healthcare groups are changing. Amanat Holdings is an investor in healthcare and education, so a partnership between a care provider and a university sits naturally within its portfolio. Similar tie-ups between hospitals and academic institutions are becoming more common in the region.

Still, the real test comes later. Success will be measured in published studies, adopted protocols and patients who recover better. If the partnership delivers even a few of those, it will have given the UAE’s long-term care sector something it needs: evidence it can call its own.

The post Cambridge Health Group and Heriot-Watt University join forces on rehabilitation research appeared first on DH Arab.

The article provided to me was cut off after its opening lines, so I can only report what it states: the partners will run a genome-wide association study (GWAS), combining Khalifa University’s genomic research with Sanofi’s expertise. I have not added details such as sample sizes, timelines or funding, because they were not in the source.

How will it work?

A GWAS scans the genomes of many people and looks for small variations that appear more often in those with a given condition than in those without it. No single variant explains a disease like asthma or COPD. The value comes from finding patterns across thousands of data points.

Here, the academic side brings the genomic research capability and the pharmaceutical side brings experience in respiratory drug development. That pairing is common in modern drug discovery. Universities hold the data and the analytical skill, and industry knows which biological targets are worth pursuing into trials.

Why does it matter?

Asthma and COPD are long-term conditions that place steady demand on clinics, emergency departments and household budgets. Treatment today is often trial and error. Two patients with the same diagnosis can respond very differently to the same inhaler or biologic therapy.

Genetic findings can change that. They can point to disease subtypes, flag who is at higher risk, and identify new drug targets. For clinicians, the promise is more precise prescribing. For health systems, it is fewer avoidable admissions.

But there is a catch. Genetic reference data has long leaned heavily toward European populations. Findings drawn from those groups don’t always transfer cleanly to Arab populations, whose genetic makeup differs, and where high rates of consanguinity shape the inheritance of some conditions. Research grounded in local data is not a nice extra. It is the only way to know whether global findings hold here.

The context

The agreement fits a clear pattern in the UAE. The Emirati Genome Programme, run out of Abu Dhabi, has set out to sequence large numbers of residents, and the country has made genomics a pillar of its preventive and personalised medicine ambitions. Saudi Arabia is moving the same way under Vision 2030, with its own genome initiatives and a push to build a domestic life sciences sector.

Partnerships like this one are how those national datasets turn into something clinical. Sequencing alone doesn’t treat anyone. Someone has to analyse the results, link them to disease, and carry the findings toward therapies.

Still, the real test lies ahead. GCC health leaders should watch for how data is governed, whether results are published openly, and whether findings reach local patients and not only global pipelines. If the study delivers, the Gulf could move from being a consumer of genetic evidence on respiratory disease to a producer of it.

The post Khalifa University and Sanofi turn to the genome to understand asthma and COPD in the Gulf appeared first on DH Arab.

The Department of Health – Abu Dhabi (DoH) made the move in collaboration with Abu Dhabi Health Data Services (ADHDS), part of M42. The rollout is emirate-wide, not a pilot limited to a few hospitals. That choice says a lot about how seriously the regulator treats the tool.

How does it work?

Malaffi connects records from public and private providers across Abu Dhabi, so a physician can see a patient’s history regardless of where the care happened. The problem is volume. A chronic patient may carry years of lab results, imaging reports, prescriptions and discharge notes from several facilities.

The AI assistant sits on top of that record. Instead of scrolling through each entry, a physician can use the assistant to pull together the relevant information and view it quickly. The tool works inside the clinician’s existing workflow, which matters because doctors rarely adopt systems that demand a separate login or extra clicks. The physician stays in charge of the decision. The assistant organizes what is already in the record, and the clinician judges what it means.

Why does it matter?

Consider the daily reality of a busy clinic. A consultation lasts minutes, and a good part of it can go to hunting through files. Cutting that search time gives physicians more minutes with the patient, and it lowers the chance that a key result or earlier diagnosis gets missed.

It also matters for equity of access. A doctor in a small private clinic now has the same summarizing tool as a colleague in a large hospital group. That levels the field in a way few technology projects manage.

But risks remain. AI summaries can be wrong or incomplete, and clinicians will need to check them against source records. Data privacy is the other test, since the assistant works with highly sensitive information. Public trust will depend on how well governance holds up.

The context

Abu Dhabi has spent years building the foundations for this step. Malaffi launched as a unified record system, and the emirate has pushed hard to position itself as a global center for health technology, with M42 as a main vehicle for that ambition. The UAE’s national AI strategy and its wider digital health agenda point the same way.

The pattern is visible across the GCC. Saudi Arabia’s Vision 2030 health transformation program leans on digital platforms and national data systems, and Qatar and Bahrain are also expanding their electronic records. Most of these systems have collected data for years. The next question is whether they can make that data useful at the point of care.

Abu Dhabi is answering that question with a concrete tool in front of every doctor. Other Gulf health authorities will watch the results closely, particularly on accuracy, physician uptake and patient safety. If the numbers are good, expect similar assistants to appear in neighboring health information exchanges soon.

The post Abu Dhabi puts an AI assistant inside every physician’s patient record appeared first on DH Arab.

M42 describes itself as a global health leader powered by artificial intelligence, technology and genomics. ADCAN Pharma brings the production side. The agreement supports wider efforts to develop the UAE’s life sciences sector, though the announcement is a framework for exploration, not a finished project. No investment figures, timelines or product lists have been made public.

How will it work?

An MoU is not a binding contract. It sets out the areas where two organizations intend to work together and gives them a basis to negotiate the details. Here, those areas are manufacturing and clinical research.

On the manufacturing side, ADCAN Pharma would provide production capability. M42 would add its data, genomic and AI expertise. On the research side, the pairing could allow trials to draw on genomic information from the local population, which is far better suited to Gulf patients than data gathered mostly in Europe or North America.

The exact structure is still to be worked out. Expect further announcements as the two sides define scope and responsibilities.

Why does it matter?

Dependence on imported medicines is a vulnerability, and the pandemic made that plain across the GCC. Local manufacturing shortens supply chains and protects access to essential drugs when global shipping is disrupted.

Clinical research matters for a different reason. Many drugs are tested on populations that look little like the Gulf’s. Genetic variation affects how patients respond to treatment, and conditions such as diabetes and certain inherited disorders are common in the region. Trials run locally, informed by genomic data, can produce evidence that is more relevant to the people who will actually take the medicine.

For business leaders, the signal is also clear. Partnerships that link manufacturers with data-driven health groups point to where investment is heading.

The context

M42 was formed in Abu Dhabi to bring together health care, genomics and AI capabilities. It sits within a national push, led by the Emirate’s health authorities, to build a life sciences sector that can compete internationally. The Emirati Genome Programme is a central piece of that effort, and it gives the UAE a genomic resource few countries in the region can match.

The move also fits a broader GCC pattern. Saudi Arabia’s Vision 2030 sets targets for localizing pharmaceutical production and expanding biotechnology. Other Gulf states are making similar choices, treating health care as both a public service and an industrial opportunity.

Still, MoUs are easy to sign and harder to deliver. The test for ADCAN Pharma and M42 will be whether this agreement turns into named projects, regulatory approvals and products on pharmacy shelves. If it does, the UAE will have a stronger claim to being a place where medicines are both made and tested. If it doesn’t, it will join a long list of well-meant announcements. Health professionals and policymakers should watch for the next stage, because that is where the real answers will appear.

The post ADCAN Pharma and M42 sign MoU to build up UAE drug manufacturing and clinical research appeared first on DH Arab.

The case combined severe childhood glaucoma, Stickler syndrome, a weakened retina and extreme pathologic myopia. Each condition is difficult by itself. Together they make almost every surgical decision a trade-off, because a step that protects one part of the eye can put another at risk. The hospital treated the patient through a multi-stage surgical journey rather than a single operation.

How did it work?

The published summary is short on technical detail, so the specifics of each procedure are not public. But the logic of staged care in a case like this is well established.

• Eye pressure has to be controlled first, because childhood glaucoma can damage the optic nerve permanently.
• The retina has to be protected, since Stickler syndrome, a connective tissue disorder, is known for raising the risk of tears and detachment.
• An extremely long, thin myopic eye leaves little margin for error in any intervention.

Spacing the surgeries lets the team assess how the eye responds before the next step. It is slower. It is also usually safer.

Why does it matter?

Because rare, layered cases are where a hospital’s real depth shows. Routine cataract and refractive work tells you little about whether a centre can coordinate glaucoma, retinal and genetic expertise around one patient over months or years.

It matters for families too. Children with Stickler syndrome and glaucoma face a lifetime of risk to their sight. Early, well-sequenced care can decide how much vision they keep into adulthood. And patients who might once have looked abroad for this kind of treatment can now find it in the Gulf.

The context

Abu Dhabi has spent years building its case as a destination for complex tertiary care, and the emirate’s health strategy leans heavily on specialised services, genomics and early intervention. The Emirati Genome Programme, for example, is built around the idea that inherited conditions should be identified sooner and managed more precisely. Stickler syndrome is exactly the type of condition that benefits from that approach.

The same pressure exists across the GCC. Saudi Vision 2030 sets out to expand specialised care and reduce overseas treatment referrals, and neighbouring states are making similar commitments. High myopia is also rising worldwide, driven partly by lifestyle and screen habits, so ophthalmology services in the region will see more complicated eyes, not fewer.

One case does not prove a system. Still, it shows what a well-resourced centre can do when several subspecialties work on a single eye. The harder test for the region is repeating that result at scale, with enough trained paediatric and retinal surgeons, and with referral pathways that reach families early.

The post A -40.00 diopter eye, and a case few hospitals would want to take on appeared first on DH Arab.

Vodafone Qatar P.Q.S.C. and Digital Delmar, a company specialising in digital healthcare solutions, telemedicine and health-sector artificial intelligence, have signed a Memorandum of Understanding (MoU). The agreement was signed in Doha on 9 November, on the sidelines of the second edition of MWC Doha 2026, and was reported by the Qatar News Agency (QNA).

The stated aim is to explore opportunities for developing smart, connected healthcare solutions. It is an exploratory deal, not a product launch. But the pairing is telling.

How will it work?

Few details have been published, and an MoU is a statement of intent rather than a contract for delivery. What the announcement does say is that the two companies will look at ways to work together. The division of labour is easy to picture. Vodafone Qatar brings connectivity and network infrastructure. Digital Delmar brings clinical software, telemedicine platforms and AI tools built for the health sector.

Combined, those strengths could support services such as remote consultations, continuous patient monitoring and data-driven diagnostics. Each depends on fast, reliable connections. Without them, a video visit freezes and a monitoring alert arrives late.

Why does it matter?

Telecom operators are moving into healthcare across the Gulf, and this deal fits that pattern. Health systems in the region are under steady pressure from rising rates of chronic disease, growing populations and demand for care that reaches people wherever they live. Connected services offer a way to stretch scarce specialist time further.

There is also a business angle. For operators, health is a new source of revenue beyond mobile subscriptions. For digital health firms, a telecom partner offers reach and technical credibility that a small company would struggle to build alone.

Still, the real test is adoption. Clinicians need tools that fit their workflow, and patients need to trust that their data is protected. Partnerships that ignore either point tend to stall.

The context

Qatar has spent years building its digital health ambitions into national strategy, in line with Qatar National Vision 2030 and its focus on a healthy population and a knowledge-based economy. Across the GCC, similar goals drive spending. Saudi Arabia’s Vision 2030 includes a large digital health programme, and the UAE has made telehealth and AI in medicine a policy priority in Dubai and Abu Dhabi.

MWC Doha itself reflects that regional push. Now in its second edition, the event gathers operators, technology vendors and government bodies, and deals like this one are a typical result. Many such agreements stay at the talking stage, so the next step to watch is whether a pilot follows.

If it does, healthcare leaders in the Gulf will have another working example of how telecom and clinical expertise can share the load.

The post Vodafone Qatar and Digital Delmar team up to build connected healthcare appeared first on DH Arab.

The operation was a Laparoscopic Totally Extraperitoneal (TEP) inguinal hernia repair using balloon dissection, combined with an umbilical hernia repair. Dr. Laurent Leyani, Consultant Bariatric and Laparoscopic Surgeon, led the team. It is the first time the hospital has done this particular technique.

The patient was an Italian violin teacher in his 50s. He had lived with left groin pain for a long time, also had an umbilical hernia, and came to Fujairah for a second opinion.

How did it work?

TEP is a demanding approach. The surgeon works in the thin space between the abdominal wall muscles and the peritoneum, the membrane lining the abdominal cavity. That means the instruments never enter the abdominal cavity itself, which is one reason surgeons favour it for groin hernias.

Creating that working space is the hard part. Dr. Leyani used a balloon space-maker, an inflatable device that gently opens the plane so the surgeon can see and operate. He then repaired the defect with soft mesh fixation, and addressed the umbilical hernia in the same sitting.

One anaesthetic, a few small incisions, two problems solved. The hospital expected the patient to be discharged the next morning.

Why does it matter?

For the patient, it means less time in hospital and, in general, less pain and a quicker return to normal life than open surgery. For a musician who relies on posture and steady hands, that counts.

For Fujairah, it matters for a different reason. Complex laparoscopic work has traditionally clustered in Dubai and Abu Dhabi. When an emirate on the east coast can offer it, residents have less reason to travel for advanced care.

Akbar Moideen Thumbay, Vice President of Healthcare Division at Thumbay Group, said the milestone reflects the group’s “continued investment in bringing advanced healthcare services closer to the community.” That is a claim worth watching, but a first case is a start, not a track record.

The context

The UAE has spent years pushing for more even access to specialist care across all seven emirates, and the private sector now carries a large share of that effort. Across the GCC, national strategies, including Saudi Vision 2030, put weight on quality, regional access and shorter hospital stays. Minimally invasive surgery fits all three.

Medical tourism is part of the picture too. This patient was a foreign resident looking for a second opinion, and he found it locally. Gulf health systems want to keep that kind of demand at home.

The real test comes next. One successful case shows capability. Repeating it safely, case after case, with consistent outcomes, is what builds trust. Hospital leaders and regulators elsewhere in the Gulf will be looking for that kind of volume and data, not only for announcements.

The post A violin teacher’s two hernias, one keyhole operation in Fujairah appeared first on DH Arab.